You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 196151 - 196160 of 202331 results
  1. Brain-enriched microRNAs detectable in plasma as biomarkers of Alzheimer's Disease

    SBC: DIAMIR, LLC            Topic: NIA

    SUMMARY One in 10 Americans aged 65 and older have Alzheimer’s disease (AD). Since AD begins with a prolonged, over 10 year-long, asymptomatic stage, a growing number of companies are developing new therapies that aim to intervene early in the progression of AD and related forms of dementia. There is thus a great need for minimally invasive diagnostic tools for primary screening of individuals w ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Low-Cost Refreshable Full-Page Braille Display with High Reliability


    Project SummaryPolyK Technologies, LLCSBIR Phase IAn estimated 314 million people live with vision impairment. Nowadays, much information and knowledge are obtained by reading from computers, tablets, and smartphones. Refreshable Braille display is becoming the mainstream tool for the blind to access digital information. In the refreshable Braille display, the up-and-down of Braille dots is indepe ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig

    SBC: EMMUNE INC            Topic: NIAID

    PROJECT SUMMARY We have developed an antibody-like HIV-1 entry inhibitor, eCD4-Ig, composed of the first two domains of CD4 fused to an antibody Fc domain and a short tyrosine-sulfated CCR5-mimetic peptide. eCD4-Ig has properties that make it an exceptionally promising tool in the fight against the HIV-1 pandemic. Specifically, it is broader than any broadly neutralizing antibody (bNAb), at least ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Community-based Brain Health Program to Address Dementia Risk (C-BBHP)

    SBC: POSIT SCIENCE CORP            Topic: NIA

    PROJECT SUMMARY The goal of the current Phase I proposal is to further develop (to pivotal trial readiness) and evaluate a community-based Brain Health Program to address dementia risk (C-BBHP) that includes multiple intervention modalities affecting diet, exercise and cognitive health designed to extend older adults’ functional independence and improve cognitive performance. This intervention m ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. ClearScope

    SBC: MICROBRIGHTFIELD, LLC            Topic: 101

    Combined in vivo and ex vivo three-dimensional (3D) whole-brain imaging of non-transgenic and transgenic animal models holds the promise of novel insights into neural network connectivity patterns. With regard to ex vivo light microscopic imaging of 3D whole-brain datasets, the best approach is brain clearing followed by whole-brain light sheet microscopy (LSM) because of its unique combination of ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Wastewater data integration and modelling to accurately predict community and organizational outbreaks due to viral pathogens


    Project Summary. The COVID-19 pandemic has magnified the need for enhanced ability to accurately anticipate future outbreaks due to novel and endemic viral pathogens. Without systematic surveillance, the ability to head off outbreaks before they occur is challenging: the data from positive human test results is often too late to prevent a major outbreak from occurring, despite substantial lockdown ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. MoodRing: A multi-stakeholder platform to monitor and manage adolescents' depression in primary care with passive mobile sensing.

    SBC: NURELM, INC.            Topic: 104

    ABSTRACT As rates of adolescent depression and suicidality continue to trend upwards, the healthcare system struggles to address the need for and lack of mental health service use. The pediatric patient-centered medical home model may improve adolescent depression outcomes by enhancing access to and coordinating care, as well as providing ongoing monitoring. Unfortunately, despite guideline recomm ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  8. SBIR Phase I:A Drop-in Sustainable Cathode Replacement that can Allow Sub-$100/kWh Li-ion Battery Packs with Improved Safety and Performance

    SBC: NANODIAN, INC.            Topic: CT

    The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project addresses the high cost and poor safety of Lithium-ion batteries in new energy applications. Low-cost and safe batteries will improve economic viability for solar energy storage, which is critical to increasing renewables penetration to above 30% of total power generation. This project advances a batt ...

    SBIR Phase I 2022 National Science Foundation
  9. SBIR Phase II: Augmenting Virtual Healthcare with Voice Biomarkers


    The broader impact of this Small Business Innovation Research (SBIR) Phase II project is to develop smart, robust healthcare infrastructure in the U.S. by leveraging machine learning and artificial intelligence to streamline clinical decision support. Voice biomarkers detect a variety of health conditions, emotions, and diseases and provide a unique, seamless feedback for real-time triage. Transfo ...

    SBIR Phase II 2021 National Science Foundation
  10. An innovative non-thiazolidinedione pan-PPAR agonist therapeutic for Alcoholic Hepatitis

    SBC: PLEIOGENIX INC            Topic: 999

    PROJECT SUMMARY Alcoholic Hepatitis (AH) is a severe and acute form of alcohol-mediated liver disease, affecting ~34% of heavy alcohol drinkers, and presents a healthcare burden of ~$2.2 billion/yearly. AH sufferers have a short life expectancy, with about ~70% dying in the first six months after presentation. Re-hospitalization occurs in nearly 40% of the patients within 90 days of their first ho ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government